A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg

Schizophrenia Clinical Trial

— DWCZP-I-1  

Official title:

Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01654601
• Other study ID #: DWCZP-I-1
• Status: Completed
• Phase: Phase 1
• First received: July 25, 2012
• Last updated: February 13, 2014
• Start date: June 2012
• Est. completion date: August 2013

Study information

• Verified date: February 2014
• Source: Dong Wha Pharmaceutical Co. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.

Description:

A randomized, 2-way crossover, open, phase I study to compare the pharmacokinetics profile of DWCZP tablet 100mg and Clozaril® tablet 100mg after a multiple-dose oral administration in schizophrenia patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: August 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

• Adult male or female within range of 20 to 60.

• Diagnosed as Schizophrenia (Note: Diagnosed with DSM-IV, ICD-10 as a standard Schizophrenia diagnostic tool).

• Administered clozapine for 3 months before signing agreement with same amount daily and who can administer clozapine 100mg twice (morning, evening) a day, total of 200mg during the study time.

• One who might be pregnant must get negative result for pregnancy test (urine or blood ß-hCG) before the randomization and during the study time, one must agree appropriate contraception. However, one who is using only hormone-contraceptive for birth control and has not been more that 1 year after Tubal ligation or menopause are excluded.

• One who understood completed about this study after the explanation is given, decided to volunteer and gave written informed consent approved by IRB to participate in study in compliance with the requirement of the entire protocol.

Exclusion Criteria:

• One who has record of hypersensitive reaction with Clozapine or other antipsychotic drug.

• WBC count less than 4,000/ml or Absolute Neutrophil count less than 2,000/ml.

• Administering hypertension drug or has orthostatic hypotension.

• One who has clinical problem with kidney or liver and include following criteria: CCr < 50mL/min; BUN > 30 mg/dl; ALT ?? AST > 3 x ULN; Total bilirubin > 2 x ULN; ALP > 2 x ULN.

• Diagnosed to have other psychiatric or neurological problems other than Schizophrenia (e.g., Organic mental disorder, severe tardive dyskinesia, idiopathic Parkinson's disease, etc).

• Record of Granulocytopenia or Myeloproliferative disorder in the past.

• Record of stomach-related problems(active Crohn's disease, vital infectious intestine disease, ulcer, acute or chronic pancreatitis etc) or surgery which can affect absorption of study drug. However, simple appendectomy or herniotomy are exceptions.

• Chronic Hepatitis B carrier, proof of Hepatitis C carrier or Hepatitis C antibody.

• Immunodeficiency diseases such as HIV positive, AIDS, had bone marrow transplantation or has blood ammonia.

• Record of seizure in 1 year before signing informed consent form or had administered anti-seizure drug before(e.g., Epilepsy, Convulsions, Myasthenia gravis, etc).

• One who constantly drinks(> 21Units/week, 1Unit = 10g of pure alcohol) or cannot stop drinking alcohol during hospitalization period.

• Smoking past 3 months before signing informed consent form or cannot stop smoking during hospitalization period.

• One who cannot attend routine blood tests.

• Bone marrow malfunction.

• Mental illness, durg addicted or in coma.

• One who has any kind of circulation imperfection and patient with depressed central nervous system.

• Major kidney and heart problem(e.g. myocarditis).

• Incurable epilepsy.

• Paralytic intestinal obstruction.

• Generic problems such as Lactose intolerance, Galactose intolerance, Lapp lactose deficiency, Glucose-Galactose absorption deficiency, etc.

• Administered barbital-related drugs and drug metabolizing enzyme inducer and inhibitor in 1 month before starting the study.

• One who had drugs that can affect on result of the study for past 10 days before the study start.

• One who had whole blood donation in 2 months or blood component donation or transfusion in 1 month before signing the informed consent form.

• Attended clinical tests or bioequivalence tests in 2 months before signing informed consent form.

• Currently pregnant or breast-feeding or has possibility of pregnancy because one is not using medically approved contraception(Note: condoms, oral contraceptive, intrauterine device, abstinence etc).

• One who is clinically significant by observations considered as unsuitable based on medical judgement by investigators.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• DWCZP
Multiple dose
• Clozaril
multiple-dose

Locations

Country	Name	City	State
Korea, Republic of	Konkuk University Hospital	Choongju
Korea, Republic of	Wonkwang University	Iksan
Korea, Republic of	Naju National Hospital	Naju
Korea, Republic of	Seoul National Hospital	Seoul
Korea, Republic of	The Catholic University of Korea, yeouido St.Mary's Hospital	Seoul

Sponsors (7)

Lead Sponsor	Collaborator
Dong Wha Pharmaceutical Co. Ltd.	DongGuk University, Konkuk University Hospital, Naju National Hospital, Seoul National Hospital, The Catholic University of Korea, Wonkwang University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Concentration of Clozapine in Plasma		Up to 12hours	Yes
Secondary	Time to Reach Maximum Concentration of Clozapine in Plasma		Up to 12hours	Yes
Secondary	Terminal Half Life of Clozapine in Plasma		Up to 12hours	Yes
Secondary	Accumulation Rate of Clozapine in Plasma		Up tp 12hours	Yes

External Links

•   Dongguk University
•   Konkuk University Hospital
•   Naju National Hospital
•   Seoul National Hospital
•   The Catholic University of Korea, Yeouido St.Mary's Hospital
•   Wonkwang University